ARCHIVES

Study Would Try to Validate EGFR FISH as Predictive Marker for Benefit from Tarceva.

This article is from The Cancer Letter archive.

Vol. 33 No. 27 | July 13, 2007

Download PDF Visit The Full Archive

Related Articles

ACS Challenged To Clarify Position On FDA Reform

March 1, 1996

In Brief: Bruce Chamber Is DeVita’s Choice as Permanent Director Of DCT; Six New RCDAs Funded In FY 1982

June 11, 1982

NCI Plans Contract To Study Cancer Research Manpower Needs; Epidemiologist State Their Case

October 7, 1977

The Cancer Letter Obtains “Confidential” Documents From Duke IRB Investigation

May 14, 2010

Scientific Process

September 25, 1998

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

July 26, 2013